Acurx Pharmaceuticals, Inc. (ACXP)
USD 0.37
(-1.02%)
USD 0.37
(-1.02%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 14.57 Million | 12.09 Million | 12.81 Million | 4.6 Million | 5.93 Million |
| Selling, General and Administrative Expenses | 8.53 Million | 7.33 Million | 10.78 Million | 2.39 Million | 2.42 Million |
| Research and Development Expenses | 6.04 Million | 4.75 Million | 2.03 Million | 2.2 Million | 3.51 Million |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 14.57 Million | 12.09 Million | 12.81 Million | 4.6 Million | 5.93 Million |
| Operating Income | -14.57 Million | -12.09 Million | -12.88 Million | -4.6 Million | -5.93 Million |
| Interest Expense | - | - | - | - | - |
| Income Tax Expense | - | -1224.00 | -66.5 Thousand | -4598.04 | -5934.25 |
| Earnings before Tax | -14.57 Million | -12.09 Million | -12.74 Million | -4.6 Million | -5.93 Million |
| Net Income | -14.57 Million | -12.09 Million | -12.68 Million | -4.6 Million | -5.93 Million |
| Earnings Per Share Basic | -1.15 | -1.12 | -1.24 | -0.46 | -0.60 |
| Earnings Per Share Diluted | -1.15 | -1.12 | -1.24 | -0.46 | -0.60 |
| Weighted Average Shares Outstanding | 12.67 Million | 10.81 Million | 10.21 Million | 9.91 Million | 9.91 Million |
| Weighted Average Shares Outstanding (Diluted) | 12.67 Million | 10.81 Million | 10.21 Million | 9.91 Million | 9.91 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | - | -12.09 Million | - | -4.6 Million | -5.93 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 4.12 Million | 4.37 Million | 5.11 Million | 14.57 Million | 3.11 Million | 3.44 Million |
| Selling, General and Administrative Expenses | 2.29 Million | 2.82 Million | 3.17 Million | - | 1.76 Million | 1.7 Million |
| Research and Development Expenses | 1.82 Million | 1.55 Million | 1.94 Million | - | 1.34 Million | 1.73 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 4.12 Million | 4.37 Million | 5.11 Million | 14.57 Million | 3.11 Million | 3.44 Million |
| Operating Income | -4.12 Million | -4.37 Million | -5.11 Million | -14.57 Million | -3.11 Million | -3.44 Billion |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -4.12 Million | -4.37 Million | -5114.59 | -14.57 Thousand | -3115.98 | 3.44 Billion |
| Earnings before Tax | -4.12 Million | -4.37 Million | -5.11 Million | -14.57 Million | -3.11 Million | -3.44 Million |
| Net Income | -4.12 Million | -4.37 Million | -5.11 Million | -14.57 Million | -3.11 Million | -3.44 Million |
| Earnings Per Share Basic | -0.26 | -0.28 | -0.38 | - | -0.24 | -0.28 |
| Earnings Per Share Diluted | -0.26 | -0.28 | -0.38 | - | -0.24 | -0.28 |
| Weighted Average Shares Outstanding | 15.82 Million | 15.47 Million | 13.46 Million | 12.67 Million | 13 Million | 12.18 Million |
| Weighted Average Shares Outstanding (Diluted) | 15.82 Million | 15.47 Million | 13.46 Million | 12.67 Million | 13 Million | 12.18 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -4.12 Million | -4.37 Million | -5.11 Million | - | -3.11 Million | -3.44 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
8542
VUL
E8X
BBN
000660
002611